Results 191 to 200 of about 1,663,582 (244)

Progress in Synthesis and Pharmacology of Telmisartan

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
Telmisartan is a benzimidazole derivative and a well‐known drug to treat hypertension. This review provides synthesis and understanding of telmisartan as an antihypertensive drug through two mechanisms of actions: RAAS inhibitor and PPARγ receptor. Effective repurposing of this drug for various diseases like chronic kidney illness, diabetes, fatty ...
Megha, Richa Srivastava, Ram Singh
wiley   +1 more source

Considerations for Menstrual Suppression in Patients With Hematologic Malignancies. [PDF]

Pharmacotherapy
Veeravalli S, Schepers A, Benitez LL, Fraga MS.   +3 more
europepmc   +1 more source

Computational, In Vitro, and In Vivo Evaluation of Benzimidazole–Pyrazole Hybrid Scaffolds as Multi‐Target Anti‐Ulcer Agents

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
The hybrid pharmacophore approach involves the combination of benzimidazole‐pyrazole moieties to form multi‐functional anti‐ulcer compounds. Molecular modeling and biological evaluations show significant proton pump inhibition, anti‐inflammatory action, antioxidant property, and remarkable prevention of gastric ulcers.
Hafiz Aamir Ali Kharl, Abdul Malik, Humaira Nadeem, Mohammad Shamsul Ola, Sara Aiman, Arif Ullah Khan, Muhammad Akmal Farooq, Humaira Muzaffar, Syed Muzzammil Masaud   +8 more
wiley   +1 more source

Symptom burden and symptom clusters in ovarian cancer patients during first-line maintenance therapy: a cross-sectional survey. [PDF]

Support Care Cancer
Xie Y, Chen Y, Sui BL, Wang Y, Fang YH, Yuan XH, Li MY, Zhang LH, Zhang Y.   +8 more
europepmc   +1 more source

Reactive Oxygen Species in Breast Cancer: From Redox Dysregulation to ROS‐Responsive Therapeutics

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT Breast cancer is the most frequently diagnosed malignancy among women worldwide, with 2.3 million new cases and approximately 670,000 deaths reported in 2022 alone. Despite advances in therapy, metastasis and acquired drug resistance remain major clinical challenges.
Marija Nikolovska, Radoslav Stojchevski, Aleksandar Eftimov, Mitko Mladenov, Dimiter Avtanski, Nikola Hadzi‐Petrushev   +5 more
wiley   +1 more source

Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports. [PDF]

Front Immunol
Huang J, Cai J, Cheng W, Wang Y.
europepmc   +1 more source

Efficacy and Safety of Initial Low‐Dose, Extended‐Interval Nivolumab Monotherapy in a 91‐Year‐Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT The incidence of non‐small cell lung cancer (NSCLC) increases with age, with approximately half of the cases diagnosed in individuals aged 70 and older. In numerous clinical trials, immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in treating NSCLC without driver gene mutations.
Dan Kou, Xiang Yan, Qi Huang, Jingye Zhong, Qiongcheng Chen, Tao Zhao, Xianhua Xu   +6 more
wiley   +1 more source

Reconsidering the Interpretation of "Recurrence-Free Survival" After Mastectomy for DCIS. Comment on Sae-sim et al. Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy. <i>Curr. Oncol.</i> 2026, <i>33</i>, 89. [PDF]

Curr Oncol
Venkataraman J, Mokbel K.
europepmc   +1 more source

An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Breast cancer remains a topic of interest due to its high mortality rate among Cameroonian women. The barks of Erythrina excelsa are traditionally used for medicinal purposes in the management of various conditions including cancer.
Jonas Walantini, Marius Trésor Kemegne Sipping, Merline Nguedia Ymele, Roland Nhouma Rebe, Joël Abel Gbaweng Yaya, Derek Tantoh Ndinteh, Dieudonné Njamen, Stéphane Zingue   +7 more
wiley   +1 more source

Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR‐Negative Ovarian Cancer Cells

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Progesterone induces rapid cellular responses in progesterone receptor (PR)‐negative ovarian cancer cells that are consistent with non‐genomic progesterone signaling. Vasohibin‐2 (VASH2), originally identified as a pro‐angiogenic factor, has recently been recognized as a tubulin carboxypeptidase involved in microtubule regulation ...
Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Kohei Tamura, Eri Suizu, Kazuki Yamamoto, Akiyo Taneichi, Yuji Takei, Hiroaki Mizukami, Hiroyuki Fujiwara   +9 more
wiley   +1 more source